Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Definium Therapeutics ( (DFTX) ) has shared an announcement.
Definium Therapeutics has launched “Rerouting Minds,” an educational campaign designed to inform healthcare providers, mental health professionals, advocates, and policymakers about the scientific evidence and therapeutic potential of pharmaceutical lysergide (LSD) in treating severe mental health disorders. By highlighting LSD’s extensive research history, proposed mechanisms of action, and emerging clinical data, the initiative aims to foster informed dialogue, increase awareness of psychedelic-based treatment options, and reinforce Definium’s positioning at the forefront of the so‑called psychedelic renaissance in psychiatric care.
The most recent analyst rating on (DFTX) stock is a Buy with a $61.00 price target. To see the full list of analyst forecasts on Definium Therapeutics stock, see the DFTX Stock Forecast page.
Spark’s Take on DFTX Stock
According to Spark, TipRanks’ AI Analyst, DFTX is a Neutral.
The score is held back mainly by weak financial performance (no revenue, sizeable ongoing losses, and heavy cash burn), partially offset by a stronger near-term setup from the earnings call (financing runway and clear Phase III catalysts) and supportive technical momentum. Valuation remains challenging due to negative earnings and no dividend support.
To see Spark’s full report on DFTX stock, click here.
More about Definium Therapeutics
Definium Therapeutics, formerly Mind Medicine (MindMed) Inc., is a late-stage clinical biopharmaceutical company focused on developing a new generation of therapeutics to address the underlying causes of psychiatric and neurological disorders. Headquartered in New York and listed on Nasdaq under the symbol DFTX, the company applies scientific rigor to psychedelic-based treatments with the goal of creating accessible, scalable solutions for severe mental health conditions amid a growing global mental health crisis.
Average Trading Volume: 1,962,988
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.48B
See more data about DFTX stock on TipRanks’ Stock Analysis page.